Publications by authors named "Gary Albert"

Claim this Profile
I
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Gary Albert

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Louis Fries, Neil Formica, Raburn M Mallory, Haixia Zhou, Joyce S Plested, Gary Albert

J Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Raburn M Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert

Lancet Infect Dis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Shabir A Madhi, Dhayendre Moodley, Sherika Hanley, Moherndran Archary, Zaheer Hoosain, Gary Albert

Lancet HIV· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Neil Formica, Raburn Mallory, Gary Albert, Michelle Robinson, Joyce S Plested

PLoS Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Paul T Heath, Eva P Galiza, David N Baxter, Marta Boffito, Duncan Browne, Alberto San Francisco Ramos, Gary Albert

N Engl J Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Gary Albert

N Engl J Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Cheryl Keech, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed

N Engl J Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
Nasreen Khalil, Helene Manganas, Christopher J Ryerson, Shane Shapera, Andre M Cantin, Gary R Albert

Eur Respir J· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.
Amy D Shapiro, Charles Nakar, Joseph M Parker, Gary R Albert, John E Moran

Blood· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
Martin R Zamora, Marie Budev, Mark Rolfe, Jens Gottlieb, Atul Humar, Gary Albert

Am J Respir Crit Care Med· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Christian Manegold, Donald Gravenor, Donald Woytowitz, Jörg Mezger, Vera Hirsh, Gary Albert

J Clin Oncol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis